In recent years, anti-PD-1/PD-L1 checkpoint blockade immunotherapy (CBI) has been approved to treat metastatic squamous cell carcinomas, including head and neck squamous cell carcinoma, lung cancer, and cervical cancer (Lyu et al., 2020). This evidence concerns the gene PDCD1 and cervical cancer.